PMID- 17338118
OWN - NLM
STAT- MEDLINE
DCOM- 20070503
LR  - 20071115
IS  - 0043-5147 (Print)
IS  - 0043-5147 (Linking)
VI  - 59
IP  - 9-10
DP  - 2006
TI  - [Serum levels of interleukin-6 and interleukin-10 in patients with multiple 
      sclerosis during intravenous immunoglobulin infusion].
PG  - 626-9
AB  - Intravenous immunoglobulin (IVIG) therapy is a recognized treatment of 
      inflammatory and autoimmune disorders and its efficacy in multiple sclerosis (MS) 
      has been proven in a few double-blind studies. IVIG has several effects on the 
      immune system that could have a beneficial influence on disease process in MS and 
      one of these effects are significant changes in serum levels of circulating 
      cytokines after IVIG infusions. As interleukin-6 (IL-6) and interleukin-10 
      (IL-10) play important role as pro- and anti-inflammatory factors, in vivo 
      modulation of these cytokines may account for immunomodulatory and 
      anti-inflammatory effect of IVIG therapy. In order to better understand mechanism 
      of action of low-dose IVIG cyclic therapy we have investigated serum levels of 
      IL-6 and IL-10 before and a day after IVIG infusion in patients with MS. MATERIAL 
      AND METHODS: Serum levels of IL-6 and IL-10 were assayed in 20 patients with MS 
      before and 24 hours after infusion of 2.5 g (n = 9) and 5 g (n = 11) of IVIG. 
      RESULTS: Significant changes of IL-6 nor IL-10 serum levels after IVIG infusions 
      in both doses of 2.5 g and 5 g were not observed. CONCLUSION: Single infusion of 
      2.5 g nor 5 g of IVIG does not alter serum levels of neither pro-inflammatory 
      IL-6 nor anti-inflammatory IL-10. As modulating influence of IVIG on the serum 
      levels of IL-6 and IL-10 seems to be dose-dependent, further investigations of 
      these cytokines levels after infusions of higher doses of IVIG might be efficient 
      in the assessment of its usability in monitoring of immune system response to 
      IVIG treatment.
FAU - Kazibutowska, Zofia
AU  - Kazibutowska Z
AD  - Z Kliniki Neurologii Katedry Neurologii Slaskiej Akademii Medycznej w Katowicach 
      Gornoslaskie Centrum Medyczne. neurologia@gcm.pl
FAU - Motta, Ewa
AU  - Motta E
FAU - Huc, Maciej
AU  - Huc M
FAU - Strzala-Orzel, Michalina
AU  - Strzala-Orzel M
FAU - Woznik, Gabriela
AU  - Woznik G
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Stezienie interleukin 6 oraz 10 w surowicy chorych na stwardnienie rozsiane, 
      leczonych wlewami dozylnych immunoglobulin.
PL  - Poland
TA  - Wiad Lek
JT  - Wiadomosci lekarskie (Warsaw, Poland : 1960)
JID - 9705467
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interleukin-6)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/blood
MH  - Interleukin-10/*blood
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*blood/*drug therapy
MH  - Serum/chemistry/immunology
MH  - Treatment Outcome
EDAT- 2007/03/07 09:00
MHDA- 2007/05/04 09:00
CRDT- 2007/03/07 09:00
PHST- 2007/03/07 09:00 [pubmed]
PHST- 2007/05/04 09:00 [medline]
PHST- 2007/03/07 09:00 [entrez]
PST - ppublish
SO  - Wiad Lek. 2006;59(9-10):626-9.